Table 1 Demographic factors for general cohort and by HBV exposure status groups (N = 150)
Cohort Demographics n (col %) | Demographics by HBV Exposure Status n (row %) | ||||
|---|---|---|---|---|---|
Total cohort (N = 150) | Not immune (N = 46) | Prior exposure (N = 65) | Immune due to vaccination (N = 39) | p-value | |
Age | |||||
24–40 | 36 (24%) | 12 (33%) | 4 (11%) | 20 (56%) | < 0.001 |
41–57 | 60 (40%) | 26 (43%) | 24 (40%) | 10 (17%) | |
58–74 | 54 (36%) | 8 (15%) | 37 (69%) | 9 (17%) | |
Race | |||||
White | 77 (51%) | 23 (30%) | 32 (42%) | 22 (29%) | 0.55 |
Black or African American | 40 (27%) | 9 (23%) | 22 (55%) | 9 (23%) | |
Hispanic or Latino | 17 (11%) | 7 (41%) | 6 (35%) | 4 (24%) | |
Other | 16 (11%) | 7 (44%) | 5 (31%) | 4 (25%) | |
Sex at birth | |||||
Male | 104 (69%) | 34 (33%) | 41 (39%) | 29 (28%) | 0.35 |
Female | 46 (31%) | 12 (26%) | 24 (52%) | 10 (22%) | |
Housing Status, current | |||||
Stable | 74 (49%) | 19 (26%) | 39 (53%) | 16 (22%) | 0.07 |
Unstable | 76 (51%) | 27 (36%) | 26 (34%) | 23 (30%) | |
Lifetime injection drug use | |||||
Yes | 137 (91%) | 43 (31%) | 60 (44%) | 34 (25%) | 0.55 |
No | 13 (9%) | 3 (23%) | 5 (38%) | 5 (38%) | |
Current injection drug use | |||||
Yes | 100 (67%) | 35 (35%) | 37 (37%) | 28 (28%) | 0.08 |
No | 50 (33%) | 11 (22%) | 28 (56%) | 11 (22%) | |
MSM | |||||
Yes | 16 (11%) | 4 (25%) | 5 (31%) | 7 (44%) | 0.23 |
No | 134 (89%) | 42 (31%) | 60 (45%) | 32 (24%) | |
HIV-positive | |||||
Yes | 6 (4%) | 0 (0%) | 3 (50%) | 3 (50%) | 0.19 |
No | 143 (96%) | 45 (31%) | 62 (43%) | 36 (25%) | |
On methadone/suboxone | |||||
Yes | 53 (35%) | 18 (34%) | 24 (45%) | 11 (21%) | 0.54 |
No | 97 (65%) | 28 (29%) | 41 (42%) | 28 (29%) | |
FIB-4 Score | |||||
< 1.25 | 88 (59%) | 32 (36%) | 28 (32%) | 28 (32%) | 0.02 |
1.25–3.25 | 50 (33%) | 12 (24%) | 29 (58%) | 9 (18%) | |
> 3.25 | 12 (8%) | 2 (17%) | 8 (67%) | 2 (17%) | |